MACE in COPD: addressing cardiopulmonary risk

Lancet Respir Med. 2024 May;12(5):345-348. doi: 10.1016/S2213-2600(24)00038-9. Epub 2024 Mar 1.

Authors

John R Hurst¹, Chris P Gale²; Global Working Group on Cardiopulmonary Risk

Collaborators

Global Working Group on Cardiopulmonary Risk:
John R Hurst, Mohit Bhutani, Jean Bourbeau, MeiLan Han, Nathaniel M Hawkins, Carolyn S P Lam, Darcy D Marciniuk, David Price, Daiana Stolz, Shelley Zieroth, Chris P Gale

Affiliations

¹ UCL Respiratory, University College London, London, UK.
² Department of Cardiology, Leeds Teaching Hospitals NHS Trust, Leeds, UK; Leeds Institute for Cardiovascular and Metabolic Medicine, University of Leeds, Leeds LS2 9JT, UK; Leeds Institute for Data Analytics, University of Leeds, Leeds, UK. Electronic address: c.p.gale@leeds.ac.uk.

PMID: 38437859
DOI: 10.1016/S2213-2600(24)00038-9

No abstract available

MeSH terms

Humans
Myocardial Infarction / epidemiology
Myocardial Infarction / prevention & control
Pulmonary Disease, Chronic Obstructive* / epidemiology
Risk Factors